Joost C M Meijers Selected Research

Plasminogen

7/2010	Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
7/2008	Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia.
1/2003	The role of the fibrinolytic system in corneal angiogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joost C M Meijers Research Topics

Disease

31	Thrombosis (Thrombus) 01/2024 - 03/2002
23	Hemorrhage 01/2024 - 11/2002
21	Inflammation (Inflammations) 06/2022 - 02/2004
17	Sepsis (Septicemia) 06/2021 - 10/2005
14	Infections 11/2018 - 06/2003
14	Pneumonia (Pneumonitis) 11/2018 - 03/2004
10	Venous Thrombosis (Deep-Vein Thrombosis) 01/2020 - 08/2002
7	Melioidosis 09/2020 - 03/2010
7	Atherosclerosis 01/2020 - 01/2003
7	Pneumococcal Pneumonia 07/2015 - 03/2004
6	Thrombophilia 08/2023 - 02/2005
6	Neoplasms (Cancer) 11/2015 - 01/2003
4	Disease Susceptibility (Diathesis) 08/2023 - 07/2004
4	Hemophilia A (Haemophilia) 08/2023 - 01/2002
4	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2023 - 08/2010
4	Activated Protein C Resistance (APC Resistance) 01/2023 - 09/2002
4	Liver Diseases (Liver Disease) 03/2022 - 03/2010
4	Disseminated Intravascular Coagulation 06/2021 - 12/2004
4	Thrombocytopenia (Thrombopenia) 09/2020 - 01/2007
4	Asthma (Bronchial Asthma) 01/2016 - 02/2014
4	Type 2 Diabetes Mellitus (MODY) 11/2011 - 02/2004
4	Endotoxemia 12/2007 - 01/2003
3	Virus Diseases (Viral Diseases) 08/2023 - 02/2014
3	Wounds and Injuries (Trauma) 01/2023 - 11/2010
3	ST Elevation Myocardial Infarction 01/2021 - 01/2016
3	Hereditary Angioedemas 01/2020 - 12/2008
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 09/2015
3	Critical Illness (Critically Ill) 04/2015 - 01/2006
3	Human Influenza (Influenza) 05/2014 - 11/2006
3	Fibrosis (Cirrhosis) 01/2014 - 07/2012
3	Myocardial Infarction 04/2010 - 12/2006
3	Thrombotic Thrombocytopenic Purpura 01/2010 - 04/2008
3	Acute Coronary Syndrome 10/2005 - 03/2002
2	von Willebrand Diseases (von Willebrand's Disease) 09/2022 - 09/2022
2	Fever (Fevers) 06/2021 - 01/2015
2	Angioedema 01/2020 - 04/2019
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2020 - 08/2009
2	Atherosclerotic Plaque (Atheroma) 01/2020 - 08/2014
2	Edema (Dropsy) 11/2019 - 11/2004
2	Factor XI Deficiency (Hemophilia C) 01/2019 - 07/2004

Drug/Important Bio-Agent (IBA)

30	Thrombin FDA Link 01/2024 - 03/2002
24	AnticoagulantsIBA 01/2023 - 11/2002
20	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
17	Protein CIBA 01/2023 - 02/2004
16	von Willebrand FactorIBA 09/2022 - 04/2008
13	Hemostatics (Antihemorrhagics)IBA 08/2023 - 01/2003
13	Prothrombin (Factor II)IBA 01/2023 - 09/2002
12	FibrinIBA 08/2023 - 03/2004
10	CytokinesIBA 01/2017 - 03/2008
9	fibrin fragment D (D-dimer)IBA 06/2022 - 02/2006
9	Thromboplastin (Tissue Factor)IBA 01/2019 - 01/2006
8	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 10/2018 - 01/2002
7	Factor XI (Plasma Thromboplastin Antecedent)IBA 08/2023 - 07/2004
7	Factor VIII (Coagulation Factor VIII)IBA 10/2018 - 07/2006
7	AntigensIBA 01/2017 - 10/2009
7	AntithrombinsIBA 03/2015 - 10/2005
6	Tissue Plasminogen Activator (Alteplase)FDA Link 10/2018 - 01/2003
6	Plasminogen InactivatorsIBA 01/2016 - 01/2006
6	Antifibrinolytic Agents (Antifibrinolytics)IBA 01/2016 - 01/2006
6	Plasminogen Activator Inhibitor 1IBA 01/2016 - 01/2009
5	Factor XII (Hageman Factor)IBA 08/2023 - 12/2006
5	AntibodiesIBA 01/2023 - 01/2002
5	Protein SIBA 09/2017 - 02/2004
5	EndotoxinsIBA 01/2017 - 07/2006
5	Fibrinolysin FDA Link 01/2016 - 01/2006
5	Heparin (Liquaemin)FDA LinkGeneric 01/2014 - 03/2002
4	Blood Coagulation Factors (Coagulation Factor)IBA 01/2023 - 12/2006
4	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2011
4	LipopolysaccharidesIBA 06/2021 - 03/2004
4	Antisense OligonucleotidesIBA 11/2018 - 11/2010
4	lipoprotein-associated coagulation inhibitor (TFPI)IBA 07/2015 - 01/2006
4	ChemokinesIBA 07/2015 - 04/2009
4	Interleukin-6 (Interleukin 6)IBA 03/2015 - 11/2005
4	Factor VIIa (Activated Factor VII)IBA 08/2014 - 01/2006
4	recombinant FVIIa (rFVIIa)FDA Link 09/2013 - 01/2002
4	Lipoproteins (Lipoprotein)IBA 12/2008 - 06/2003
3	Monoclonal AntibodiesIBA 01/2023 - 12/2014
3	ThrombomodulinIBA 01/2023 - 04/2013
3	Factor V (Coagulation Factor V)IBA 03/2022 - 03/2015
3	Factor Xa (Coagulation Factor Xa)IBA 03/2022 - 01/2021
3	CholesterolIBA 01/2021 - 02/2004
3	Factor XIII (Coagulation Factor XIII)IBA 07/2019 - 07/2012
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2018 - 01/2003
3	Peptide Hydrolases (Proteases)FDA Link 10/2015 - 06/2011
3	Endothelial Protein C ReceptorIBA 05/2014 - 01/2013
3	Plasminogen Activators (Plasminogen Activator)IBA 04/2014 - 01/2003
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2014 - 03/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 04/2010
3	PlasminogenIBA 07/2010 - 01/2003
3	C-Reactive ProteinIBA 04/2010 - 04/2005
2	Complement System Proteins (Complement)IBA 01/2022 - 01/2006
2	Vitamin K FDA Link 01/2022 - 01/2018
2	Dacarbazine (DIC)FDA LinkGeneric 06/2021 - 12/2004
2	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 11/2010
2	MicroRNAs (MicroRNA)IBA 01/2020 - 09/2015
2	BradykininIBA 01/2020 - 11/2019
2	Peptides (Polypeptides)IBA 11/2019 - 11/2017
2	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2019 - 03/2016

Therapy/Procedure

13	Therapeutics 08/2023 - 03/2002
2	Contraception (Birth Control) 01/2020 - 09/2012